Related Experiment Video
Updated: Dec 22, 2025

Biomechanical Analysis Methods to Assess Professional Badminton Players' Lunge Performance
Published on: June 11, 2019
Trying for a BRAF Slam Dunk
1Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu rlo@mednet.ucla.edu.
Abstract:
The first basket clinical trial testing the BRAF inhibitor vemurafenib resulted in evidence of activity in 13 unique cancer types with BRAF V600 mutations, but the response rates were variable. Therefore, different cancer histologies with the same driver oncogene display different degrees of oncogenic pathway addiction.See related article by Subbiah et al., p. 657.
Insights
Vemurafenib showed activity in 13 cancers with BRAF V600 mutations. However, response rates varied, indicating different cancer types rely differently on the BRAF oncogene.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- The BRAF V600 mutation is a key driver oncogene in various cancers.
- Targeted therapies like vemurafenib have shown promise against BRAF-mutated cancers.
- Basket trials are designed to test a single drug in multiple cancer types harboring a specific mutation.
Purpose of the Study:
- To evaluate the activity of the BRAF inhibitor vemurafenib across multiple cancer types with BRAF V600 mutations.
- To investigate the variability in response rates to vemurafenib among different cancer histologies.
Main Methods:
- A first-in-human basket clinical trial design.
- Administration of the BRAF inhibitor vemurafenib.
- Assessment of drug activity and response rates in patients with 13 distinct cancer types harboring BRAF V600 mutations.
Main Results:
- Vemurafenib demonstrated clinical activity in all 13 tested cancer types with BRAF V600 mutations.
- Significant variability in response rates was observed across the different cancer histologies.
- This suggests differential reliance on the BRAF-driven oncogenic pathway based on cancer type.
Conclusions:
- The BRAF inhibitor vemurafenib exhibits activity across a spectrum of BRAF V600-mutated cancers.
- Cancer histology significantly influences the degree of oncogenic pathway addiction, impacting treatment response.
- These findings highlight the complexity of targeted therapy efficacy and the need for histology-specific considerations.
Related Concept Videos
Slump Test
Concrete is poured into the mold in three layers to conduct the test. Each layer is compacted 25 times with a steel tamping rod, which has a five-eighths-inch diameter and a rounded end, to ensure even distribution and eliminate...
Hydraulic Jump
Bricks
Soft mud bricks are shaped in molds with high moisture content and can be...
Brick Cutting Techniques
Cut bricks are categorized by size. Bricks cut to half their original length are called half-bats, while those cut to three-fourths their length are known as three-fourth bats.
Special types of...
Brick Durability, Strength, and Appearance
Brick Sizes
Modular bricks are the most common type and are sized to include the mortar joint, which is essential for...

